ERBB2 and breast cancer: High SDC3 expression was significantly linked to improved RFS (n = 4929), particularly in the HER2-negative, luminal A, luminal B, and basal subtype, as well as in patients receiving neoadjuvant chemotherapy, suggesting a potential stage-specific role for SDC3 in breast cancer metastasis.